Randomized, double‐blind, phase III study to evaluate the efficacy and safety of once‐daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes

@inproceedings{Kaku2017RandomizedDP,
  title={Randomized, double‐blind, phase III study to evaluate the efficacy and safety of once‐daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes},
  author={Kohei Kaku and Shuuji Sumino and Masafumi Katou and Yuya Nishiyama and Yoshinobu Kinugawa},
  booktitle={Diabetes, obesity & metabolism},
  year={2017}
}
This randomized, double-blind, phase III study evaluated the efficacy and safety of once-daily treatment with alogliptin (25 mg once daily), alone or with metformin hydrochloride (500 mg once daily or 250 mg twice daily), in Japanese patients with type 2 diabetes. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to the end of treatment (week 24). The least squares (LS) mean (standard error) change in HbA1c from baseline to the end of treatment (week 24) was 0.16 (0… CONTINUE READING
1 Citations
8 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Mechanisms underlying metformininduced secretion of glucagonlike peptide1 from the intestinal L cell

  • AJ Mulherin, AH Oh, H Kim
  • Endocrinology
  • 2011

Similar Papers

Loading similar papers…